Key result
Patients with chronic severe primary mitral regurgitation had significantly higher myocardial fibrosis compared to autopsy controls (median CVFmean 14.6% vs 3.3%, P<0.001), a difference that was present even before the onset of symptoms.
Why the study?
It was unknown whether myocardial fibrosis secondary to MR is present before the onset of symptoms or myocardial dysfunction.
Does cardiovascular magnetic resonance-derived extracellular volume correlate with histological myocardial fibrosis, left ventricular function, and exercise capacity in patients with chronic severe primary mitral regurgitation?
Observational (n=120)
Blinded analysis of histology and CMR
Yes
Does cardiovascular magnetic resonance-derived extracellular volume correlate with histological myocardial fibrosis, left ventricular function, and exercise capacity in patients with chronic severe primary mitral regurgitation?
In patients with chronic severe primary mitral regurgitation, myocardial fibrosis is increased even before symptom onset, and CMR-derived extracellular volume serves as a useful global marker of myocardial status that correlates with LV function and exercise capacity.
Answers are grounded in this paper and cite their sources.
Myocardial fibrosis precedes symptoms in severe primary MR; hypothesis-generating for CMR ECV in risk stratification.
BACKGROUND: Myocardial fibrosis occurs in end-stage heart failure secondary to mitral regurgitation (MR), but it is not known whether this is present before onset of symptoms or myocardial dysfunction. This study aimed to characterise myocardial fibrosis in chronic severe primary MR on histology, compare this to tissue characterisation on cardiovascular magnetic resonance (CMR) imaging, and investigate associations with symptoms, left ventricular (LV) function, and exercise capacity. METHODS: ) compared to autopsy controls without cardiac pathology. RESULTS: max: R = - 0.22, P = 0.030). CONCLUSIONS: Patients with chronic primary MR have increased fibrosis before the onset of symptoms. Due to the patchy nature of fibrosis, CMR derived ECV may be a better marker of global myocardial status. Clinical trial registration Mitral FINDER study; Clinical Trials NCT02355418, Registered 4 February 2015, https://clinicaltrials.gov/ct2/show/NCT02355418.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted an observational in Chronic severe primary mitral regurgitation (n=120). Chronic severe primary mitral regurgitation vs. Autopsy controls without cardiac pathology was evaluated on Myocardial fibrosis (collagen volume fraction, CVFmean) (p=<0.001). Patients with chronic severe primary mitral regurgitation had significantly higher myocardial fibrosis compared to autopsy controls (median CVFmean 14.6% vs 3.3%, P<0.001), a difference that was present even before the onset of symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: